Uncommon cause of fever in a child with steroid-dependent nephrotic syndrome

Sidharth Kumar Sethi¹, Shyam Bansal¹, Ronith Chakraborty², Rahul Jain², Nikita Wadhwani¹, and Rupesh Raina²,³

¹Kidney Institute, Medanta, The Medicity Hospital, Gurgaon, Haryana, India, and ²Akron General Medical Center, and ³Akron Children’s Hospital, Akron, OH, USA

Abstract. Background: Children with nephrotic syndrome are vulnerable to developing infections due to a state of relative immunodeficiency, malnourishment, and use of immunosuppression. Case characteristics: We herein report the case of a 3-year-old child with steroid-dependent nephrotic syndrome who presented to us with fever of unknown origin. Observation: The child was found to have an atypical mixed infection with mycoplasma and cytomegalovirus. Outcome: The infection completely resolved with appropriate treatment and lowering of immunosuppression. Message: Persistently febrile pediatric patients, especially in the setting of recent immunosuppression and absence of otherwise-identified infectious pathogens, should be screened for atypical mixed infections.

Background

Children with nephrotic syndrome (NS) are vulnerable to developing a myriad of infections due to their state of relative immunodeficiency and malnourishment caused by urinary losses of immunoglobulins and albumin as well as the use of potent immunosuppressants. The incidence of infectious complications in this cohort has been reported to vary between 32 and 38% in different studies [1, 2, 3, 4, 5, 6, 7, 8]. The spectrum is versatile but frequently includes spontaneous bacterial peritonitis, septicemia, urinary tract and skin infections, upper and lower respiratory tract infections, meningitis, and rarely, viral infections (herpes simplex virus, varicella-zoster virus, measles) [6, 7]. Apart from increasing the morbidity and mortality, infections also induce relapses of NS and steroid resistance [8]. The incidence and frequency of serious infections has been shown to be higher in the setting of steroid-dependent NS, frequently-relapsing and steroid-resistant cases of nephrotic syndrome [8, 9]. We herein present a 3-year-old steroid-dependent child with NS with an uncommon mixed infection following a prolonged immunosuppressive treatment regimen.

Case report

A 3-year-old girl presented at our clinic with daily remittent fever of 2 weeks’ duration that was unresponsive to antipyretics. She was experiencing high-grade fever, fluctuating between 38 and 40 °C and occurring up to 3 times a day. Her past medical history was significant for NS diagnosed 1 year prior. She was started on a standard immunosuppressive regimen consisting of prednisolone (9 mg on alternate days). She could not be weaned off steroids despite repeated trials and required a high-dose regimen to stay in remission. In view of her high-threshold steroid dependence, the parents were counselled regarding the use of oral cyclophosphamide or mycophenolate mofetil (MMF) therapy. With parental consent, she was started on MMF (1,000 mg/m²/day). The patient was subsequently lost to follow-up. At the time of presentation, the child was in remission with no proteinuria and with normal serum albumin levels.

Four months into treatment for NS, she developed remittent bouts of high fever for 2 weeks, after which she returned at our hospital seeking medical care. After reviewing her medical records, it was determined that the patient was on both MMF (1,000 mg/m²/day) and prednisolone (9 mg on alternate days). She had been noncompliant with the prescribed corticosteroid taper. Her local cli-
nian did not taper the initial prescription of 9 mg alternate-day steroid (her weight being 20 kg). On admission, she was noted to have hepatosplenomegaly and leucocytosis (Table 1). Empiric treatment was commenced with intravenous ceftriaxone and stress doses of prednisolone. At presentation, two sets of blood and urine cultures were sent for analysis, and they reported no growth.

Serologic testing for dengue, malaria, typhoid, and rickettsia were non-reactive. Her serum ANA (anti-nuclear antibodies) and complement protein (C3, C4) levels were normal. The child had a normal nutrition state, with both height and weight percentiles being at 50th percentile for age and sex as per Centers for disease control and prevention (CDC) standards. A transthoracic echocardiogram failed to demonstrate any vegetation suggestive of infective endocarditis, and the chest X-ray was normal. Ultrasound of the abdomen showed no abnormality apart from hepatosplenomegaly. A pediatric hematology review was obtained, and a bone marrow aspiration study was undertaken, which showed cellular, reactive bone marrow with normal hematopoietic cells, and no evidence of leukemia or hemophagocytosis. Computed tomography scan of chest and abdomen showed hepatosplenomegaly and diffuse ground glass haze in both lung fields (Figure 1).

On further investigation, she was found to have raised IgG and IgM antibody titers (17.4 AU/mL and 27 AU/mL, respectively: normal value < 10 AU/mL) to *Mycoplasma pneumoniae*. A repeat sample during the convalescent period showed a 4-fold rise in

---

**Table 1. Lab investigations.**

| Test                                      | Result         | Normal Range          |
|-------------------------------------------|----------------|-----------------------|
| Hemoglobin (g/dL)                         | 13.5 (12 – 15) |                       |
| TLC (×10⁹/mL)                             | 14500          | (4 – 11)              |
| Platelets (×10⁹/mL)                       | 456 (150 – 400)|                       |
| Creatinine (mg/dL)                        | 0.4 (0.6 – 1.2)|                       |
| BUN (mg/dL)                               | 16 (7 – 20)    |                       |
| ALT (U/L)                                 | 22 (8 – 20)    |                       |
| AST (U/L)                                 | 20 (8 – 20)    |                       |
| ALP (U/L)                                 | 154 (30 – 100)|                       |
| C-reactive protein (mg/L)                 | 5.7 (0 – 10)   |                       |
| Quantitative DNA PCR                      |                |                       |
| EBV                                        | Negative       |                       |
| CMV                                        | 56,340 copies/mL |                       |
| Anti-nuclear antibodies                    | Non-reactive   |                       |
| Anti-mycoplasma antibodies (AU/mL)        |                |                       |
| IgG                                        | 17.4 (< 10)    |                       |
| IgM                                        | 27 (< 10)      |                       |
| Blood and urine cultures                  | Sterile        |                       |
| Chest X-ray                               | Normal         |                       |
| Ultrasound abdomen                         | Hepatosplenomegaly |                   |

ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; BUN = blood urea nitrogen; CMV = cytomegalovirus; EBV = epstein-barr virus; TLC = total leukocyte count.

---

Figure 1. Computed tomography scan of chest and abdomen show hepatosplenomegaly and diffuse ground glass haze in both lung fields.
IgG titer against *Mycoplasma pneumonia*, thus confirming the infection. Subsequent addition of azithromycin was followed by a remarkable improvement in her clinical condition. A quantitative viral PCR assay for Epstein-Barr virus (EBV) DNA was negative. PCR testing for cytomegalovirus (CMV) DNA revealed 56,340 copies/mL, and her MMF was stopped. Within a week of instituting intravenous ganciclovir therapy, the viral load declined to 180 copies/mL. A repeat PCR assay 1 week later was negative for CMV DNA. She was finally switched to oral valganciclovir and was completely asymptomatic at the time of discharge with undetectable viremia, normal leucocyte count, and absence of organomegaly. Currently, the child has been in remission for the last 6 months, without immunosuppressive therapy.

**Discussion**

Opportunistic infections occur in the setting of intensified immunosuppression involving high-dose steroids, antimetabolites, and biologics. MMF is a new immunosuppressant recently being used as a steroid-sparing agent in pediatric steroid-sensitive NS. It has now been used in multiple retrospective studies and a recent randomized controlled trial [10, 11, 12]. Fever is a common manifestation of CMV disease, but an infrequent cause of fever of unknown origin (FUO) [13]. The incidence of CMV antigenemia increases manifold with the use of combination immunosuppression. Apart from FUO, it can also present with a mononucleosis-like picture, but more serious complications including CMV colitis or pneumonitis may also result in immunocompromised patients (especially oncology and post-transplant patients) [1, 2].

CMV should be suspected in FUO patients in the presence of otherwise unexplained leukopenia, relative lymphopenia, thrombocytopenia, atypical lymphocytosis, or transaminitis. Prompt CMV testing using viral load assay should be sought in such cases. The presence of typical cytopathic changes associated with CMV in tissue specimens or a very high serum IgM titer (in the absence of rheumatoid factor) can also suffice to establish a diagnosis [14].

*Mycoplasma pneumoniae* has been sparsely cited as a cause of FUO [15, 16, 17]. The clinical course of mycoplasma infection in immunosuppressed patients may follow a variable pattern, and a prolonged illness may result. Immunocompromised patients are more likely to present with pneumonia as compared with upper respiratory tract infection or bronchiolitis, which are commonly encountered among immunocompetent patients. The clinical manifestations, however, appear to be similar, and these include fever, malaise, and cough with no or mild sputum production [18, 19, 20, 21, 22]. It has been shown to cause varied extra-pulmonary involvement in the form of septic arthritis, cerebellar ataxia, Guillain-Barré syndrome, transverse myelitis, and aseptic meningitis [23, 24, 25].

*Mycobacterium tuberculosis*, a well-known cause of FUO in both normal and immunocompromised patients, should also be considered early in the course of disease in patients coming from areas with high endemicity. Fungal opportunistic infections, yet another cause of morbidity in immunocompromised population, are not a frequent cause of FUO, with the exception of histoplasma, which has been reported to result in prolonged febrile illness with subacute pulmonary symptoms in several studies. Common non-infectious causes like malignancies, adrenal insufficiency, vasculitides, and drug fever can also lead to FUO and should be considered during the work-up [26, 27, 28].

**Conclusion**

We suggest that persistently febrile pediatric patients, especially in the setting of recent immunosuppression and absence of otherwise-identified infectious pathogens, should be screened for atypical mixed infections like CMV and mycoplasma.

**Funding**

There is no funding to report.

**Conflict of interest**

There is no conflict of interest.
References

[1] Vora SB, Englund JA. Cytomegalovirus in immuno-compromised children. Curr Opin Infect Dis. 2015; 28: 323-329. CrossRef PubMed

[2] Russell MY, Palmer A, Michaels MG. Cytomegalovirus infection in pediatric immunocompromised hosts. Infect Disord Drug Targets. 2011; 11: 437-448. CrossRef PubMed

[3] Pai SY, Logan BR, Griffith LM, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Hanson GC, Fil蒂ovich AH, Jyonouchi S, Sullivan KE, Small TN, Burroughs L, Skoda-Smith S, Haight AE, Grizzle A, Pulsipher MA, Chan KW, Feucht RN, Haddad E, et al. Transplantation outcomes for severe combined immunodeficiency, 2000 – 2009. N Engl J Med. 2014; 371: 434-446. CrossRef PubMed

[4] Ugartes-Torres A, Hoegh-Petersen M, Liu Y, Zhou F, Williamson TS, Quinlan D, Sy S, Roa L, Khan F, Fonseca K, Russell JA, Storck J. Donor serostatus has an impact on cytomegalovirus-specific immunity, cytomegaloviral disease incidence, and survival in seropositive hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2011; 17: 574-585. CrossRef PubMed

[5] Boekh M, Leisenring W, Riddell SR, Bowden RA, Huang ML, Myerson D, Stevens-Ayers T, Flowers ME, Cunningham T, Corey L. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003; 101: 407-414. CrossRef PubMed

[6] Wei C-C, Yu I-W, Lin H-W, Tsai A-C. Occurrence of infection among children with nephrotic syndrome during hospitalizations. Nephrology (Carlton). 2012; 17: 681-688. CrossRef PubMed

[7] Soeiro EMD, Koch VH, Fujimura MD, Okay Y. Influence of nephrotic state on the infectious profile in childhood idiopathic nephrotic syndrome. Rev Hosp Clin Fac Med Sao Paulo. 2004; 59: 273-278. CrossRef PubMed

[8] Gulati S, Kher V, Gupta A, Arora P, Rai PK, Sharma BK. Spectrum of infections in Indian children with nephrotic syndrome. Pediatr Nephrol. 1995; 9: 431-434. CrossRef PubMed

[9] Senguttuvan P, Ravanan K, Prabhu N. Infections encountered in childhood nephrotics in a pediatric renal unit. Indian J Nephrol. 2004; 14: 85-88.

[10] Nandi M, Mandal SK, Samanta M, Majhi A, Das MK. Efficacy of mycophenolate mofetil as a remission maintaining agent in idiopathic childhood nephrotic syndrome. Indian J Nephrol. 2019; 29: 34-41. PubMed

[11] Sinha A, Puraswami M, Kalaivani M, Goyal P, Hari P, Bagga A. Efficacy and safety of mycophenolate mofetil versus levamisole in frequently relapsing nephrotic syndrome: an open-label randomized controlled trial. Kidney Int. 2019; 95: 210-218. CrossRef PubMed

[12] Querfeld U, Weber LT. Mycophenolate mofetil for sustained remission in nephrotic syndrome. Pediatr Nephrol. 2018; 33: 2253-2265. CrossRef PubMed

[13] Mickail N, Nausheen S, Cunha BA. Fever of unknown origin (FUO): cytomegalovirus (CMV) in an immuno-competent host. Infect Dis Pract. 2007; 21: 629-630.

[14] Cunha BA. Cytomegalovirus pneumonia: community-acquired pneumonia in immunocompetent hosts. Infect Dis Clin North Am. 2010; 24: 147-158. CrossRef PubMed

[15] Jayantha UK. Mycoplasma pneumoniae: an unrecognized cause of pyrexia of unknown origin. Sri Lanka Journal of Child Health. 2006; 35: 125-127. CrossRef

[16] Ali-Ahmed F, Halalau A. Mycoplasma pneumonia: An unrecognized cause of fever of unknown origin in an adult. Case Report Infect Dis. 2017; 2017: 6854913. CrossRef PubMed

[17] Dominguez-Castellano A, Cerro R, Rico MA, Rojo JL. [Prolonged fever as an unusual form of presentation of a Mycoplasma pneumoniae infection]. Enferm Infec Microbiol Clin. 1994; 12: 42-43. PubMed

[18] Schwerk N, Hartmann C, Baumann U, Pape L, Ehrich JH, Hansen G. Chronic Mycoplasma pneumoniae infection in a child after renal transplantation. Pediatr Transplant. 2010; 14: E26-E29. CrossRef PubMed

[19] Takei T, Morazumi M, Ozaki H, Fujita H, U hubaka K, Kobayashi I, Kadota K, Miyamae T, Tokota S, Ivata S, Takahashi T. Clinical features of Mycoplasma pneumoniae infections in the 2010 epidemic season: report of two cases with unusual presentations. Pediatr Neonatol. 2013; 54: 402-405. CrossRef PubMed

[20] Arca M, Bellot A, Dupont C, Bach N, Eckart P, Penniello-Valette MJ, Brouard J. [Two uncommon extrapulmonary forms of mycoplasma pneumoniae infection]. Arch Pediatr. 2015; 20: 378-381. CrossRef PubMed

[21] Narita M. Pathogenesis of extrapulmonary manifestations of Mycoplasma pneumoniae infection with special reference to pneumonia. J Infect Chemother. 2010; 16: 162-169. CrossRef PubMed

[22] Schwerk N, Hartmann C, Baumann U, Pape L, Ehrich JH, Hansen G. Chronic Mycoplasma pneumoniae infection in a child after renal transplantation. Pediatr Transplant. 2010; 14: E26-E29. CrossRef PubMed

[23] Tomaino J, Keegan T, Miloh T, Kerkar N, Mercer S, Birge M, Roca J, Suchy F, Aron R. Stevens-Johnson syndrome after Mycoplasma pneumonia infection in pediatric post-liver transplant recipient: case report and review of the literature. Pediatr Transplant. 2012; 16: E74-E77. CrossRef PubMed

[24] Mian AN, Farney AC, Mendley SR. Mycoplasma hominis septic arthritis in a pediatric renal transplant recipient: case report and review of the literature. Am J Transplant. 2005; 5: 183-188. CrossRef PubMed

[25] Rohner P, Schnyder I, Nitin B, Schrenzel J, Lew D, Ramla T, Garbino J, Jacomo V. Severe Mycoplasma hominis infections in two renal transplant patients. Eur J Clin Microbiol Infect Dis. 2004; 23: 203-204. CrossRef PubMed

[26] Cunha BA, Lortholary O, Cunha CB. Fever of unknown origin: a clinical approach. Am J Med. 2015; 128: e1138-e1138.e15. CrossRef PubMed

[27] Mulders-Manders C, Simon A, Bleeker-Rovers C. Fever of unknown origin. Clin Med (Lond). 2015; 15: 280-284. CrossRef PubMed

[28] Heersch EC, Oh RC. Prolonged febrile illness and fever of unknown origin in adults. Am Fam Physician. 2014; 90: 91-96. PubMed